证券代码：002907 证券简称：华森制药 公告编号：2025-060 重庆华森制药股份有限公司 关于公司药品生产许可证变更及通过 GMP 符合性检查 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日收到重庆市药品 监督管理局颁发的《药品生产许可证》（许可证编号：渝 20150018）和 2 项产 品的《药品 GMP 符合性检查告知书》（编号：渝 GMP20250070、编号：渝 GMP20250073），具体情况如下： 一、《药品生产许可证》变更内容 1.重庆市荣昌区工业园区三车间小合成生产线：原料药（阿戈美拉汀）， 通过药品生产质量管理规范符合性检查，予以登记； 3.重庆市荣昌区昌州街道板桥路 143 号 502 车间冻干粉针剂生产线：注射用 艾司奥美拉唑钠（国药准字H20243180）通过药品生产质量管理规范符合性检查。 *** 二、变更后的《药品生产许可证》具体内容 企 业 名 称 ：重庆华森制药股份有限公司 许可证编号 ：渝 20150018 社 会 信 用 代 码 ：915002262038 ...

Core Viewpoint - Huason Pharmaceutical has received a new drug production license and passed GMP compliance checks, which will enhance production capacity but will not significantly impact short-term performance [1] Group 1: Regulatory Changes - The company announced the receipt of a new drug production license from the Chongqing Drug Administration [1] - Two products, including injectable Esomeprazole Sodium, have been added to the production license [1] Group 2: GMP Compliance - The small-scale synthesis production line in the Rongchang Industrial Park has passed the GMP compliance check [1] - Both injectable Esomeprazole Sodium and the raw material drug (Agomelatine) have successfully passed GMP compliance checks [1] Group 3: Impact on Operations - These changes are expected to improve the company's capacity utilization and promote large-scale production [1] - However, the company does not anticipate a significant impact on its performance in the short term [1]

奥睿药业已于近日完成相关工商变更登记手续，取得了成都高新技术产业开 发区市场监督管理局核发的《营业执照》。现将变更后的《营业执照》基本信息 公告如下： 准后方可开展经营活动，具体经营项目以相关部门批准文件或许可证件为准）一 般项目：医学研究和试验发展；技术服务、技术开发、技术咨询、技术交流、技 术转让、技术推广；专用化学产品销售（不含危险化学品）；第一类医疗器械销 售；第二类医疗器械销售（除依法须经批准的项目外，凭营业执照依法自主开展 经营活动）。 一、基本情况 重庆华森制药股份有限公司（以下简称"公司"）于 2025 年 5 月 13 日召开 第三届董事会第十七次会议，审议通过《关于公司全资子公司受让成都奥睿药业 有限公司股权的议案》，在成都奥睿药业有限公司（以下简称"奥睿药业"）股 权变更完成后，公司及其控股子公司重庆华森英诺生物科技有限公司（下称"华 森英诺"）合计持有奥睿药业 66%的股权，华森英诺为奥睿药业之控股股东，华 森制药为奥睿药业之实际控制人。详情可查阅公司于 2025 年 5 月 15 日发布的 《关于公司全资子公司受让成都奥睿药业有限公司股权及公司为全资子公司提 供对外担保的公告》(公告 ...

证券代码：002907 证券简称：华森制药 公告编号：2025-059 重庆华森制药股份有限公司 关于控股子公司完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、基本情况 重庆华森制药股份有限公司（以下简称"公司"）于 2025 年 5 月 13 日召开 第三届董事会第十七次会议，审议通过《关于公司全资子公司受让成都奥睿药业 有限公司股权的议案》，在成都奥睿药业有限公司（以下简称"奥睿药业"）股 权变更完成后，公司及其控股子公司重庆华森英诺生物科技有限公司（下称"华 森英诺"）合计持有奥睿药业 66%的股权，华森英诺为奥睿药业之控股股东，华 森制药为奥睿药业之实际控制人。详情可查阅公司于 2025 年 5 月 15 日发布的 《关于公司全资子公司受让成都奥睿药业有限公司股权及公司为全资子公司提 供对外担保的公告》(公告编号：2025-040）。 奥睿药业已于近日完成相关工商变更登记手续，取得了成都高新技术产业开 发区市场监督管理局核发的《营业执照》。现将变更后的《营业执照》基本信息 公告如下： 1、企业名称：成都奥睿药业有限公司 7、 ...

证券代码：002907 证券简称：华森制药 公告编号：2025-058 重庆华森制药股份有限公司 关于公司药品生产许可证变更的公告 | 企 | 业 | | 名 | 称 ：重庆华森制药股份有限公司 | | --- | --- | --- | --- | --- | | 许 | 可 | 证 | 编 | 号 ：渝 20150018 | | 社 | 会 信 | | 用 代 | 码 ：915002262038944463 | | 分 | | 类 | | 码 ：AhzyBhzChDh | | 注 | 册 | | 地 | 址 ：重庆市荣昌区工业园区 | | 法 | 定 | 代 | 表 | 人 ：游洪涛 | | 企 | 业 | 负 | 责 | 人 ：游洪涛 | | 质 | 量 | 负 | 责 | 人 ：邓林 | | 质 | 量 | 受 | 权 | 人 ：王茜 | | 生 | 产 | 负 | 责 | 人 ：周帮建 | | 有 | 效 | | 期 | 至 ：2030 年 06 月 29 日 | 生产地址和生产范围 ：重庆市荣昌区工业园区：颗粒剂，粉针剂，散剂，冻干 粉针剂，原料药，软胶囊剂，小容量注射剂，硬胶囊 剂，片剂，吸入溶 ...

Policy Developments - The National Healthcare Security Administration (NHSA) held the first session of a series of discussions on supporting innovative drugs and medical devices, with over 20 representatives from pharmaceutical companies, research institutions, and medical organizations participating. The meeting emphasized the NHSA's commitment to supporting true innovation and the importance of a comprehensive value assessment for innovative products to enhance healthcare resource utilization and better serve public health [2]. Drug and Device Approvals - Shanghai Pharmaceuticals announced that its subsidiary's tranexamic acid injection has received approval from the National Medical Products Administration (NMPA) after passing the consistency evaluation for generic drugs. This drug is primarily used for various bleeding conditions caused by primary fibrinolysis [4]. - Huason Pharmaceutical received re-registration approval for three drugs from the Chongqing Drug Administration, including Ganqi Bingmei Tablets, Liuwei Anshen Capsules, and Silotazol Tablets [5]. - Huiren Pharmaceutical's subsidiary received approval for the listing of methochlorpromazine hydrochloride raw materials, which are used for preventing postoperative nausea and vomiting, as well as treating nausea related to migraines and radiation therapy. Additionally, the subsidiary received a medical device registration certificate for a sterile, single-use syringe [6]. Capital Market Activities - ST Jingfeng announced the sale of a 51% stake in its subsidiary Jiangxi Yanhua Pharmaceutical to Jiangxi Shaoyang Pharmaceutical for a price of 142,500 yuan. Following this transaction, Jiangxi Yanhua will no longer be included in the company's consolidated financial statements [8]. Industry Events - Sichuan University West China Hospital successfully completed the first implanted brain-machine interface surgery in Western China for a patient with spinal cord injury, allowing the patient to control a mechanical hand using brain signals [10][11]. - Samsung Medical's subsidiary signed a procurement framework contract in Brazil worth approximately 341 million yuan, which represents 2.33% of the company's audited revenue for 2024 [12].

Group 1 - Haitong Development reported a net profit of 86.87 million yuan for the first half of 2025, a year-on-year decrease of 64.14% [1] - Haitong Development achieved an operating income of 1.8 billion yuan, a year-on-year increase of 6.74% [1] - Crystal Integrated expects a net profit increase of 39.04% to 108.55% for the first half of 2025, with projected revenue between 5.07 billion yuan and 5.32 billion yuan [1] Group 2 - Aerospace Universe anticipates a net profit increase of 50.59% for the first half of 2025, with a projected net profit of 34.38 million yuan [2] - Aerospace Universe's net profit excluding non-recurring gains is expected to grow by 94.90% [2] Group 3 - Guodian Power reported a total power generation of 206.03 billion kWh for the first half of 2025, a year-on-year decrease of 3.61% [3] - The company's market-based transaction electricity accounted for 91.84% of the total electricity sold [3] Group 4 - Shanghai Pharmaceuticals announced that its tranexamic acid injection has passed the consistency evaluation for generic drugs [5] - The drug is primarily used for treating various bleeding disorders [5] Group 5 - Sanyou Chemical received approval to issue up to 900 million yuan in technology innovation corporate bonds [7] - The bond issuance is valid for 24 months from the date of approval [7] Group 6 - Baiyuntian's BAT4406F injection drug has received approval for clinical trials for additional indications [9] - The drug is a next-generation fully human anti-CD20 antibody [9] Group 7 - Huason Pharmaceutical received three drug re-registration approval notices [10] - The approved drugs include Ganji Bingmei tablets and other formulations [10] Group 8 - Shanying International plans to establish the Zhiyuan Fund with a total scale of 100 million yuan [13] - The fund will primarily invest in product companies related to industrial scenarios [13] Group 9 - Yiqiu Resources announced the sale of two properties in Malaysia for a total of approximately 3.67 million yuan [15] - The sale is part of the company's asset management strategy [15] Group 10 - Guizhou Bailing plans to apply for loans totaling no more than 920 million yuan from multiple banks [16] - The loans will be used to replace maturing loans and supplement working capital [16] Group 11 - Samsung Medical's subsidiary won a transformer procurement contract in Brazil worth approximately 341 million yuan [16] - The contract is part of the company's expansion into international markets [16] Group 12 - Changying Tong expects a net profit increase of 72.12% to 110.33% for the first half of 2025 [17] - The projected revenue is between 173 million yuan and 211 million yuan [17] Group 13 - Canqin Technology anticipates a net profit increase of 50.14% to 61.85% for the first half of 2025 [17] - The expected revenue is between 286 million yuan and 290 million yuan [17] Group 14 - Daya Shengxiang signed a lease agreement with an annual rent of 17 million yuan for a production facility [18] - The lease term is for 3 years and 4 months, including a 4-month rent-free period [18] Group 15 - Zhongzai Zihuan announced the resignation of its general manager due to work adjustments [20] - The company will appoint an interim general manager while searching for a permanent replacement [20] Group 16 - Fuwei Co. received a project notification from a well-known luxury brand for seat development [22] - The total sales amount for the project is expected to reach 4.9 billion yuan [22] Group 17 - Meili Technology's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [26] - The issuance is subject to further approval from regulatory authorities [26] Group 18 - Jinzhik Technology announced a stock suspension due to potential control changes [27] - The suspension is expected to last no more than two trading days [27] Group 19 - Zhongtian Technology plans to distribute a cash dividend of 3 yuan per 10 shares [28] - The dividend distribution date is set for July 25, 2025 [28] Group 20 - Huahai Chengke plans to distribute a cash dividend of 0.2002 yuan per share [30] - The dividend distribution date is set for July 29, 2025 [30] Group 21 - Dasheng Intelligent won a smart transportation project contract worth 122 million yuan [31] - The project involves comprehensive monitoring systems for urban rail transit [31] Group 22 - Dongyue Silicon reported a fire incident affecting production operations [32] - The fire has been controlled, but the extent of damage is still being assessed [32] Group 23 - Shaanxi Guotou A reported a net profit of 726 million yuan for the first half of 2025, a year-on-year increase of 5.74% [35] - The company's operating income decreased by 2.95% [35] Group 24 - Yibo Technology announced a plan to reduce shareholding by up to 3% [37] - The reduction is due to the shareholder's funding needs [37] Group 25 - Xiling Information announced a stock suspension due to potential control changes [39] - The suspension is expected to last no more than two trading days [39] Group 26 - Tianli Lithium Energy plans to reduce shareholding by 4.55% through block trading [40] - The reduction is due to the fund's operational timeline nearing its end [40] Group 27 - Sihui Fushi announced plans for a combined shareholding reduction of up to 3% [42] - The reduction is due to the shareholders' personal funding needs [42] Group 28 - Jinma Leisure announced a plan for a combined shareholding reduction of up to 4.83% [44] - The reduction is due to personal funding needs of the controlling shareholder and executives [44] Group 29 - *ST Zitian's stock may be terminated due to financial reporting issues [46] - The company is under regulatory scrutiny for failing to rectify its financial statements [46]

（二）六味安神胶囊 | | | | 药 | 品 | | 通 | 用 | 名 | 称：甘桔冰梅片 | | --- | --- | --- | --- | --- | --- | --- | | 受 | | | 理 | | | 号：CYZZ2418814 渝 | | 通 | | 知 | 书 | | 编 | 号：2025R037108 | | 剂 | | | | | | 型：片剂 | | 规 | | | | | | 格：糖衣片，片心重 0.2g | | 注 | | 册 | | 分 | | 类：中药 | | 药 | 品 | 注 | 册 | 标 | 准 编 | 号：《中国药典》2020 年版一部 | | 药 | 品 | | 批 | 准 | 文 | 号：国药准字 Z20026258 | | 药 | | 品 | 有 | | 效 | 期：24 个月 | | | | 药 品 批 准 文 号 | | | | 有 效 期：至 2030 年 04 月 28 日 | | 审 | | 批 | | 结 | | 论：经审查，本品符合《药品注册管理办法》的有关 规定，同意再注册。 | 证券代码：002907 证券简称：华森制药 公告编号：20 ...

Group 1 - Airo Energy (688717.SH) plans to reduce its shareholding by up to 0.78% of the total share capital within three months after 15 trading days due to personal funding needs [1] - Aopu Optoelectronics (002338.SZ) intends to reduce its shareholding by up to 240,000 shares, representing 1% of the total share capital, within 90 days after 15 trading days [1] - Placo New Materials (300811.SZ) completed a reduction of 1.01% of its shares, while shareholder Mei Jianjun reduced 8,134 shares, accounting for 0.0476% of the total share capital [1] Group 2 - Boqian New Materials (605376.SH) plans to reduce its shareholding by up to 261,600 shares, which is 1% of the total share capital, through block trading within three months after 15 trading days [1] - Boying Special Welding (301468.SZ) completed a reduction of 3.99% of its shares, totaling 394,480 shares [1] - Surveying and Mapping Co., Ltd. (300826.SZ) plans to reduce its shareholding by up to 50,000 shares, accounting for 0.03% of the total share capital, within three months after 15 trading days [1] Group 3 - Deyi Cultural Creation (300640.SZ) plans to reduce its shareholding by up to 300,000 shares, which is 0.0965% of the total share capital, within three months after 15 trading days [3] - Dingsheng New Materials (603876.SH) intends to reduce its shareholding by up to 3% of the total share capital through various trading methods within three months after 15 trading days [3] - Pan-Asia Micro透 (688386.SH) terminated its reduction plan early, having reduced 2.38% of its shares, bringing its holding to 4.95% [3] Group 4 - Guangpu Co., Ltd. (300632.SZ) plans to reduce its shareholding by up to 8,474,900 shares, which is 3% of the total share capital, within three months after 15 trading days [3] - Guorui Technology (300600.SZ) has reduced its shareholding by 7,297,300 shares, accounting for 2.48% of the total share capital, bringing its holding to 19.97% [3] - Hengtong Co., Ltd. (603223.SH) plans to reduce its shareholding by up to 21,425,600 shares, which is 3% of the total share capital, within three months after 15 trading days [4] Group 5 - Hongbao Li (002165.SZ) plans to reduce its shareholding by up to 14,705,400 shares, representing 2% of the total share capital, within three months after 15 trading days [4] - Hongquan IoT (688288.SH) reduced its shareholding by 869,977 shares, accounting for 0.86% of the total share capital, bringing its holding to 12.80% [4] - Huace Film and Television (300133.SZ) reduced its shareholding by 2.6 million shares, which is 0.14% of the total share capital, bringing its holding to 18.19% [4] Group 6 - Huada Jiutian (301269.SZ) plans to reduce its shareholding by up to 8,144,100 shares, which is 1.5% of the total share capital, within three months after 15 trading days [5] - Huqi Environmental Protection (300929.SZ) plans to reduce its shareholding by up to 1,312,500 shares and 8,800 shares by its concerted actors [5] - Huazheng New Materials (603186.SZ) plans to reduce its shareholding by up to 114,600 shares and 10,300 shares by its management [5] Group 7 - Jinan Technology (300412.SZ) plans to reduce its shareholding by up to 14,932,700 shares and 1,683,000 shares by its board member [5] - Jinma Amusement (300756.SZ) plans to reduce its shareholding by up to 4,712,000 shares, 2,017,000 shares, 508,200 shares, and 372,800 shares by its shareholders [6] - Longxin Zhongke (688047.SH) completed its reduction plan, with shareholders reducing a total of 588,000 shares [6] Group 8 - Limin Co., Ltd. (002734.SZ) completed its reduction plan, with a total reduction of 1.5 million shares, accounting for 0.3434% of the total share capital [7] - Longhua New Materials (301149.SZ) completed its reduction plan, with a total reduction of 986,600 shares, accounting for 0.2294% of the total share capital [7] - Lvtong Technology (301322.SZ) plans to reduce its shareholding by up to 4,829,300 shares, which is 3.39% of the total share capital, within three months after 15 trading days [7] Group 9 - Meidixi (688202.SH) plans to reduce its shareholding by up to 2 million shares, which is 1.49% of the total share capital, within three months after 15 trading days [8] - Nanjing Julong (300644.SZ) completed its reduction plan, with shareholders reducing a total of 62,300 shares [8] - Run Du Co., Ltd. (002923.SZ) plans to reduce its shareholding by up to 10,046,800 shares, which is 3% of the total share capital, within three months after 15 trading days [8]

| 合 | 计 | 4,175,800 | | 1 | | | --- | --- | --- | --- | --- | --- | | 本次权益变动方式 | | 通过证券交易所的集中交易 | | □ | | | （可多选） | | 通过证券交易所的大宗交易 | | ☑ | | | | | 其他 | | □（请注明） | | | | | 3．本次变动前后，成都地建及其一致行动人拥有上市公司权益的股份情况 | | | | | 股东 | | 本次变动前持有股份 | | 本次变动后持有股份 | | | 名称 | 股份性质 | 股数(股) | 占总股本 | 股数(股) | 占总股本比 | | | | | 比例(%) | | 例(%) | | 合计持有股份 | | 169,065,675 | 40.49 | 164,889,875 | 39.49 | | 成都 地建 | 其中：无限售 条件股份 | 169,065,675 | 40.49 | 164,889,875 | 39.49 | | 有限售 | | 0 | 0 | 0 | 0 | | 条件股份 | | | | | | | 游 | 合计持有股份 | 72,422, ...